Commodity Channel Index
|Bid||0.00 x 1000|
|Ask||6.89 x 3200|
|Day's Range||6.00 - 6.53|
|52 Week Range||1.54 - 7.70|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 -- Tiziana Life Sciences plc (Nasdaq:.
NEW YORK and LONDON , March 11, 2020 /CNW/ -- Tiziana Life Sciences plc (TLSA) (TILS.L) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the "Offering") of American Depositary Shares ("ADSs") on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares")) at a price to the public of $3.00 per ADS raising gross proceeds of approximately $10 million (before deducting underwriting discount, commissions and offering expenses).
UK biotech Tiziana Life Sciences Plc said Wednesday its TZLS-501 treatment could be used for patients with the coronavirus that causes COVID-19 and are at risk of respiratory failure. The company is accelerating development of the treatment with Novimmune SA, a Swiss biotech company. "Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood," the company said in a statement. "An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness." Shares were up more than 300% premarket. The stocks of many small biotechs and medical device companies that have made announcements relating to the virus have rallied hard as the illness has spread around the world, even though experts caution it will take a long time to develop treatments.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...